While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...
Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...
Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...
Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...
MediciNova has completed full patient enrolment in the COMBAT-ALS Phase IIb/III clinical trial of MN-166 (ibudilast) as a ...
Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...
AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...
Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.
Reduced demand from international markets and increased regulatory complexity are among the challenges that tariffs are ...
Johnson & Johnson said the combination was investigated in 49 patients with newly diagnosed multiple myeloma. Image credit: PixelBiss / Shutterstock.com Johnson & Johnson’s (J&J’s) multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback